Xin Lang Cai Jing·2026-02-26 21:40Core Viewpoint - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced the self-examination results regarding insider trading related to the spin-off of its subsidiary Fosun Antengene (Chengdu) Biopharmaceutical Co., Ltd. for listing on the Hong Kong Stock Exchange [1] Group 1: Insider Trading Self-Examination - The self-examination period was from April 28, 2025, to January 22, 2026 [1] - Some institutions and individuals engaged in trading Fosun Pharmaceutical A-shares during the self-examination period [1] - The company conducted share buybacks and equity incentive repurchases, leading to changes in shareholding [1] Group 2: Findings and Conclusions - The independent financial advisor, China International Capital Corporation, had accounts that engaged in trading based on independent investment decisions [1] - A few employees and direct relatives of directors also conducted small-scale stock transactions [1] - The self-examination concluded that no insider trading occurred related to the spin-off, and the trading actions were based on public information [1] Group 3: Progress of the Spin-off - The relevant proposals for the spin-off were approved by the company's board of directors in October 2025 and January 2026 [1] - The spin-off process is currently underway [1] - Both independent financial and legal advisors stated that the identified trading activities do not pose substantial legal obstacles to the spin-off, provided that commitments are fulfilled [1]